Veracyte announced that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research, AACR, Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. "Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs," said Corinne Danan, general manager of Veracyte’s Biopharma business unit. "The abstracts accepted for presentation at AACR 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to continually enhancing and expanding the services available to these partners."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VCYT:
- Veracyte provides statement on impact of events surrounding Silicon Valley Bank
- Veracyte sees FY23 revenue $325M-$335M, consensus $329.57M
- Veracyte reports Q4 EPS (5c), consensus (15c)
- Biotech Alert: Searches spiking for these stocks today
- Veracyte: Value of test for men with high risk prostate cancer validated
